Investor Presentation Q1 2022

7 Investor presentation First three months of 2022 International Operations Diabetes care sales grew across all regions, mainly driven by GLP-1 performance Reported Diabetes care sales and growth per IO geography GLP-1 patients and value market share in IO DKK billion 18 13% Number of ■Insulin I GLP-1 Growth at CER Patients (millions) 4 Novo NordiskⓇ Value market share 75% 60.1% 60% 60% 12 3 51.3% Geographical regions 15% 2 1% 38% 0% 6 27% 101% 1 4% 104% -6% 2% 0 0 ΙΟ EMEA China ROW Feb 2020 Feb 2021 45% 37.0% 36.1% 30% 22.0% 15% 2.1% 0% Feb 2022 GLP-1 patients -Victoza •OzempicⓇ -RybelsusⓇ -dulaglutide -NN GLP-1 Source: IQVIA MAT, Feb 2022 (Spot rate). Note that the market share and patient numbers are based on countries with IQVIA coverage IO: International operations; NN: Novo Nordisk; pp: Percentage points; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; RoW: Rest of World

View entire presentation